Date: Feb 27th, 2018
NanoMab To Initiate FIH for 99mTc-NM-01 at SGH
Shanghai, China, February 27th, 2018. NanoMab announced that it has decided to initiate FIH with NM-01, which is the company’s non-small cell lung cancer (NSCLC) program.
The kick off meeting was held at Shanghai General Hospital (SGH).
The primary objective of this study is to evaluate safety, tolerability and pharmacokinetics of NM-01.
99mTc-NM-01 is a camelid single domain antibody-based imaging agent for the non-invasive and whole body assessment of PD-L1 expression in patients before or during immuno-oncology treatment.